1. Mekaj, A, Mekaj, Y, Duci, S, Miftari, E. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967.
Google Scholar | Crossref | Medline2. Patel, MR, Mahaffey, KW, Garg, J, et al.. ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
Google Scholar | Crossref | Medline | ISI3. Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
Google Scholar | Crossref | Medline | ISI4. Granger, CB, Alexander, JH, McMurray, JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
Google Scholar | Crossref | Medline | ISI5. Ruff, CT, Giugliano, RP, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962.
Google Scholar | Crossref | Medline | ISI6. Larsen, TB, Skjoth, F, Nielsen, PB, Kjældgaard, JN, Lip, GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
Google Scholar | Crossref | Medline7. Barnes, GD, Gu, X, Haymart, B, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI2 experience. Thromb Res. 2014;134:294-299.
Google Scholar | Crossref | Medline8. Schulman, S, Kearon, C. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. J Thromb Haemost. 2005;3:692-694.
Google Scholar | Crossref | Medline | ISI9. Kaatz, S, Ahmad, D, Spyropoulos, AC, Schulman, S. Subcommittee on control of anticoagulation. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119-2126.
Google Scholar | Crossref | Medline | ISI10. Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
Google Scholar | Crossref | Medline | ISI11. Pisters, R, Lane, DA, Nieuwlaat, R, de Vos, CB, Crijns, HJGM, Lip, GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138:1093-1100.
Google Scholar | Crossref | Medline | ISI12. Witt, DM . What to do after the bleed: resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016;2016(1):620-624. doi:10.1182/asheducation-2016.1.620.
Google Scholar | Crossref | Medline13. Kuramatsu, JB, Gerner, ST, Schellinger, PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-836. doi:10.1001/jama.2015.0846.
Google Scholar | Crossref | Medline14. Albrecht, JS, Liu, X, Baumgarten, M, et al. Benefits and risks of anticoagulation resumption following traumatic brain injury. JAMA Intern Med. 2014;174(8):1244-1251.
Google Scholar | Crossref | Medline15. Poli, D, Antonucci, E, Dentali, F, et al.. Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology. 2014;82(12):1020-1026.
Google Scholar | Crossref | Medline16. Qureshi, W, Mittal, C, Patsias, I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J CardiolAm J Cardiol. 2014;113(14):662-668.
Google Scholar | Crossref | Medline17. Majeed, A, Wallvik, N, Eriksson, J, et al.. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost. 2017;117(3):491-499.
Google Scholar | Crossref | Medline18. Milling, TJ, Spyropoulos, AC. Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. Am J Med. 2016;129(suppl 11):S54-S63.
Google Scholar | Crossref | Medline19. Tomaselli, GF, Mahaffey, KW, Cuker, A, et al.. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2020;76(5):594-622.
Google Scholar | Crossref | Medline20. Kirchhof, P, Benussi, S, Kotecha, D, et al. ESC scientific document group, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(Issue 38):2893-2962.
Google Scholar | Crossref | Medline